CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: A 15-year monocentric experience

References

• Murphy S B, Bowman W P, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt's lymphomas and B cell (Sig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 1732–1739
   PubMed Web of Science ®Google Scholar
• Patte C, Philip T, Rodary C, Zucker J M, Behrendt H, Gentet J C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123–132
   PubMed Web of Science ®Google Scholar
• Schwenn M R, Blattner S R, Lynch E, Weinstein H J. HiC-COM: a 2 month-intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133–138
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Ludwig W D, Lampert F, Harbott J, Henze G, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of BFM group. Blood 1992; 80: 2471–2478
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, Ludwig W D, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-Cell neoplasms with tailored intensification of therapy: a report of the Berlin – Frankfurt – Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294–3306
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non- Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stages – a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359–372
   PubMed Web of Science ®Google Scholar
• Magrath I T, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–934
   PubMed Web of Science ®Google Scholar
• Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998; 25(Suppl 4)33–39
   PubMed Web of Science ®Google Scholar
• Bowmann W P, Shuster J J, Cook B, Griffin T, Behm F, Pullen J, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small non-cleaved cell lymphoma: a Pediatric Oncology Group Study. J Clin Oncol 1996; 14: 1252–1261
   PubMed Web of Science ®Google Scholar
• Atra A, Imeson J D, Hobson R, Gerrard M, Hann I M, Eden O B, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000; 82: 1396–1402
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370–3379
   PubMed Web of Science ®Google Scholar
• Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo G S, Collini P, et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol 2002; 20: 2783–2788
   PubMed Web of Science ®Google Scholar
• Cairo M S, Krailo M D, Morse M, Hutchinson R J, Harris R E, Kjeldsberg C R, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate (‘Orange’) in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a Children's Cancer Group Report. Leukemia 2002; 16: 594–600
   PubMed Web of Science ®Google Scholar
• Cairo M S, Sposto R, Perkins S L, Meadows A T, Hoover-Regan M L, Anderson J R, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience. Br J Haematol 2003; 120: 660–670
   PubMed Web of Science ®Google Scholar
• Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948–958
   PubMed Web of Science ®Google Scholar
• Lacasce A, Howard O, Li S, Fisher D, Weng A, Neuberg D, Shipp M. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45: 761–767
   PubMed Web of Science ®Google Scholar
• Mead G M, Sydes M R, Walewski J, Grigg A, Hatton C S, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264–1274
   PubMed Web of Science ®Google Scholar
• Wang E S, Straus D J, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 15: 1196–1205
   Web of Science ®Google Scholar
• Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82: 160–165
   PubMed Web of Science ®Google Scholar
• Goldman S C, Holcenberg J S, Finklestein J Z, Hutchinson R, Kreissman S, Johnson F L, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998–3003
   PubMed Web of Science ®Google Scholar
• Pui C H, Mahmoud H H, Wiley J M, Woods G M, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697–704
   PubMed Web of Science ®Google Scholar
• Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002; 13: 789–795
   PubMed Web of Science ®Google Scholar
• Atra A, Pinkerton C R, Bouffet E, Norton A, Hobson R, Imeson J D, et al. Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols. Eur J Cancer 2004; 40: 1346–1350
   PubMed Web of Science ®Google Scholar
• Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol 2003; 15: 695–711
   Web of Science ®Google Scholar